tiprankstipranks
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
CTNM
Contineum Therapeutics, Inc. Class A
RESEARCH TOOLSreports
Want to see CTNM full AI Analyst Report?

Contineum Therapeutics, Inc. Class A (CTNM) Stock Forecast & Price Target

220 Followers
See the Price Targets and Ratings of:

CTNM Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Contineum
Therapeutics, Inc. Class A
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CTNM Stock 12 Month Forecast

Average Price Target

$23.40
▲(66.43% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Contineum Therapeutics, Inc. Class A in the last 3 months. The average price target is $23.40 with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 66.43% change from the last price of $14.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,16.22153846153846,17.203076923076924,18.184615384615384,19.166153846153847,20.147692307692306,21.12923076923077,22.11076923076923,23.092307692307692,24.073846153846155,25.055384615384614,26.036923076923074,27.018461538461537,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.867692307692307,16.495384615384616,17.123076923076923,17.75076923076923,18.378461538461536,19.006153846153847,19.633846153846154,20.26153846153846,20.889230769230767,21.516923076923078,22.144615384615385,22.77230769230769,{"y":23.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.24,15.298461538461538,15.356923076923078,15.415384615384616,15.473846153846154,15.532307692307693,15.590769230769231,15.649230769230769,15.707692307692307,15.766153846153847,15.824615384615385,15.883076923076922,15.941538461538462,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.24,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$23.40Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CTNM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (NYSE: ATR) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
JonesTrading Analyst forecast on CTNM
Debanjana Chatterjee
JonesTrading
JonesTrading
$26
Buy
84.92%
Upside
Reiterated
07/31/26
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
LifeSci Capital Analyst forecast on CTNM
Gaurav Maini
LifeSci Capital
LifeSci Capital
$24
Buy
70.70%
Upside
Reiterated
07/31/26
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
RBC Capital Analyst forecast on CTNM
Brian Abrahams
RBC Capital
RBC Capital
$22→$23
Buy
63.58%
Upside
Assigned
07/30/26
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)
Morgan Stanley Analyst forecast on CTNM
Sean Laaman
Morgan Stanley
Morgan Stanley
$14→$16
Hold
13.80%
Upside
Reiterated
05/14/26
Contineum price target raised to $16 from $14 at Morgan StanleyContineum price target raised to $16 from $14 at Morgan Stanley
Stifel Nicolaus Analyst forecast on CTNM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$29→$28
Buy
99.15%
Upside
Reiterated
05/08/26
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)
Robert W. Baird Analyst forecast on CTNM
Charles Moore
Robert W. Baird
Robert W. Baird
$14→$20
Buy
42.25%
Upside
Reiterated
03/06/26
Contineum price target raised to $20 from $14 at BairdContineum price target raised to $20 from $14 at Baird
Jefferies Analyst forecast on CTNM
Faisal Khurshid
Jefferies
Jefferies
$22→$21
Buy
49.36%
Upside
Reiterated
12/15/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM), Xoma (NASDAQ: XOMA) and Applied Therapeutics (NASDAQ: APLT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on CTNM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (NYSE: ATR) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)
JonesTrading Analyst forecast on CTNM
Debanjana Chatterjee
JonesTrading
JonesTrading
$26
Buy
84.92%
Upside
Reiterated
07/31/26
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
LifeSci Capital Analyst forecast on CTNM
Gaurav Maini
LifeSci Capital
LifeSci Capital
$24
Buy
70.70%
Upside
Reiterated
07/31/26
Analyst Initiates Buy on Contineum, Citing PIPE-791’s Differentiated IPF Profile and Favorable Risk-Reward Ahead of Key 2026 Readthrough
RBC Capital Analyst forecast on CTNM
Brian Abrahams
RBC Capital
RBC Capital
$22→$23
Buy
63.58%
Upside
Assigned
07/30/26
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)
Morgan Stanley Analyst forecast on CTNM
Sean Laaman
Morgan Stanley
Morgan Stanley
$14→$16
Hold
13.80%
Upside
Reiterated
05/14/26
Contineum price target raised to $16 from $14 at Morgan StanleyContineum price target raised to $16 from $14 at Morgan Stanley
Stifel Nicolaus Analyst forecast on CTNM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$29→$28
Buy
99.15%
Upside
Reiterated
05/08/26
Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)
Robert W. Baird Analyst forecast on CTNM
Charles Moore
Robert W. Baird
Robert W. Baird
$14→$20
Buy
42.25%
Upside
Reiterated
03/06/26
Contineum price target raised to $20 from $14 at BairdContineum price target raised to $20 from $14 at Baird
Jefferies Analyst forecast on CTNM
Faisal Khurshid
Jefferies
Jefferies
$22→$21
Buy
49.36%
Upside
Reiterated
12/15/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM), Xoma (NASDAQ: XOMA) and Applied Therapeutics (NASDAQ: APLT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Contineum Therapeutics, Inc. Class A

3 Months
Myles MinterWilliam Blair
Success Rate
5/7 ratings generated profit
71%
Average Return
+52.07%
Copying Myles Minter's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +52.07% per trade.
1 Year
Debanjana ChatterjeeJonesTrading
Success Rate
9/9 ratings generated profit
100%
Average Return
+85.30%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +85.30% per trade.
2 Years
Debanjana ChatterjeeJonesTrading
Success Rate
9/9 ratings generated profit
100%
Average Return
+101.09%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +101.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CTNM Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
3
7
4
6
Buy
3
3
4
2
4
Hold
2
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
7
13
7
11
In the current month, CTNM has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CTNM average Analyst price target in the past 3 months is 23.40.
Each month's total comprises the sum of three months' worth of ratings.

CTNM Financial Forecast

CTNM Earnings Forecast

Next quarter’s earnings estimate for CTNM is -$0.45 with a range of -$0.51 to -$0.39. The previous quarter’s EPS was -$0.40. CTNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year CTNM has Performed in-line its overall industry.
Next quarter’s earnings estimate for CTNM is -$0.45 with a range of -$0.51 to -$0.39. The previous quarter’s EPS was -$0.40. CTNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year CTNM has Performed in-line its overall industry.
No data currently available

CTNM Sales Forecast

Next quarter’s sales forecast for CTNM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CTNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year CTNM has Performed in-line its overall industry.
Next quarter’s sales forecast for CTNM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CTNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year CTNM has Performed in-line its overall industry.

CTNM Stock Forecast FAQ

What is CTNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Contineum Therapeutics, Inc. Class A’s 12-month average price target is 23.40.
    What is CTNM’s upside potential, based on the analysts’ average price target?
    Contineum Therapeutics, Inc. Class A has 66.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CTNM a Buy, Sell or Hold?
          Contineum Therapeutics, Inc. Class A has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Contineum Therapeutics, Inc. Class A’s price target?
            The average price target for Contineum Therapeutics, Inc. Class A is 23.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $16.00. The average price target represents 66.43% Increase from the current price of $14.06.
              What do analysts say about Contineum Therapeutics, Inc. Class A?
              Contineum Therapeutics, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of CTNM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.